Assessment of total fracture risk in parkinsonian patients: risk reduction by evaluating and modifying single, individual risk factors

E. Hof (1a), W. Götz (2), M. Werner (1b)
1a Klinikzentrum Lindenallee, Abteilung für Orthopädie (Bad Schwalbach);
1b Klinikzentrum Lindenallee, Abteilung für Neurologie (Bad Schwalbach);
2 Parkinson-World GbR (Wildeshausen)

Problem

Parkinson’s disease is known to be an independent, specific risk factor for proximal femoral fractures (2).

Various single fracture risks, some of which cannot be modified like old age, gender, history of low impact fractures and others that can be modified like prevalent osteoporosis constitute an individual’s total fracture risk (1,4,5).

Assessing total fracture risk and identifying single risk factors that will respond to treatment leads to a better understanding of the effects of various treatment options thus helping to significantly reduce total fracture risk.

Reduction of total fracture risk as one important clinical outcome measure in treating Parkinson’s disease has to be kept in mind in order to cost effectively treat osteoporosis that maybe prevalent in such patients (6,8).

There are very few studies that have investigated the prevalence of osteoporosis in Parkinson’s disease.

We assessed the prevalence of osteoporosis in a Parkinson’s disease clinical cohort as a single individual risk for fractures with regard to assessing total fracture risk and to generally recommending screening of parkinsonian patients for osteoporosis.
**Method**

From 26.07.2007 – 14.08.2008 58 consenting inpatients from our neurological ward with a confirmed diagnosis of Parkinson’s disease participated. All patients had bone density measured by dual energy x-ray absorptiometry. Further data, including age, gender, ethnical background, history of multiple falling, history of dyskinesia, BMI, duration of disease, severity of disease (Hoehn-Yahr stage) were collected.

**RESULTS**

33 of 58 patients were men (56.9%)  
25 of 58 patients were women (43.1%)

Median age of the men: 72.7 (58-83.9)  
Median age of the women: 72.5 (53.2-93.8)

All patients had Caucasian background

Median BMI of the men: 28.6 (20-35.9)  
Median BMI of the women: 25.8 (17.9-35.6)

Mean duration of disease in whole sample: 9 years (1-25 years)

Disease severity: 44.8 % of patients had reached Hoehn-Yahr-stage 3.  
13.8 % of patients had reached a higher stage  
41.4 % of patients had reached a lower stage

History of multiple falling: 68.9 % of whole sample  
Dyskinesias: 20.7% of whole sample
CONCLUSIONS

The overall prevalence of osteoporosis in parkinsonian patients is considerable. It is substantially higher compared to the normal population but does not exceed that of other people of similar age (1,3).

We generally recommend osteoporosis-screening in female parkinsonian patients who are older than 50 years and in male parkinsonian patients who are older than 60 years regardless of duration of disease and severity of disease.

In younger patients we recommend screening only if there are additional clinical risk factors like history of low impact fractures or history of multiple falling.

Total fracture risk in parkinsonian patients can substantially be reduced by identifying and treating prevalent osteoporosis that has to be regarded as one of the most important single risk factors.

Literature: